Aptevo Therapeutics Inc (NASDAQ:APVO) was the target of a large decrease in short interest in December. As of December 15th, there was short interest totalling 357,460 shares, a decrease of 46.2% from the November 30th total of 664,081 shares. Based on an average daily trading volume, of 441,879 shares, the days-to-cover ratio is presently 0.8 days. Currently, 2.1% of the company’s stock are sold short.
A number of research firms have recently issued reports on APVO. ValuEngine downgraded Aptevo Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, November 10th. Piper Jaffray Companies reissued an “overweight” rating and set a $6.00 price target on shares of Aptevo Therapeutics in a research report on Thursday, October 5th.
In other news, VP Randy Joe Maddux purchased 25,000 shares of the company’s stock in a transaction dated Wednesday, November 15th. The shares were acquired at an average price of $2.76 per share, with a total value of $69,000.00. Following the transaction, the vice president now owns 25,000 shares of the company’s stock, valued at $69,000. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 15.60% of the stock is currently owned by corporate insiders.
Institutional investors and hedge funds have recently bought and sold shares of the company. Dimensional Fund Advisors LP grew its position in shares of Aptevo Therapeutics by 8.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,056,729 shares of the biotechnology company’s stock worth $2,187,000 after buying an additional 78,109 shares in the last quarter. Legal & General Group Plc boosted its position in Aptevo Therapeutics by 11,751.3% during the second quarter. Legal & General Group Plc now owns 393,701 shares of the biotechnology company’s stock valued at $815,000 after purchasing an additional 390,379 shares in the last quarter. Finally, Precept Management LLC bought a new stake in Aptevo Therapeutics during the second quarter valued at about $1,210,000. 32.13% of the stock is currently owned by institutional investors and hedge funds.
Aptevo Therapeutics (APVO) opened at $4.68 on Friday. Aptevo Therapeutics has a 12-month low of $1.15 and a 12-month high of $4.85. The company has a debt-to-equity ratio of 0.19, a quick ratio of 7.67 and a current ratio of 7.76. The stock has a market capitalization of $99.86 and a price-to-earnings ratio of -2.57.
Aptevo Therapeutics Company Profile
Aptevo Therapeutics Inc is a biotechnology company. The Company is focused on oncology and hematology therapeutics. The Company is engaged in the discovery, development, commercialization and sale of oncology and hematology therapeutics. The Company’s technology is the ADAPTIR (modular protein technology) platform.
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.